The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications - PubMed (original) (raw)
. 2001 Jul 27;20(33):4519-27.
doi: 10.1038/sj.onc.1204623.
Affiliations
- PMID: 11494147
- DOI: 10.1038/sj.onc.1204623
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications
T Hideshima et al. Oncogene. 2001.
Abstract
In this study we demonstrate that tumor necrosis factor alpha (TNFalpha) triggers only modest proliferation, as well as p44/p42 mitogen-activated protein kinase (MAPK) and NF-kappaB activation, in MM.1S multiple myeloma (MM) cells. TNFalpha also activates NF-kappaB and markedly upregulates (fivefold) secretion of interleukin-6 (IL-6), a myeloma growth and survival factor, in bone marrow stromal cells (BMSCs). TNFalpha in both a dose and time dependent fashion induced expression of CD11a (LFA-1), CD54 (intercellular adhesion molecule-1, ICAM-1), CD106 (vascular cell adhesion molecule-1, VCAM-1), CD49d (very late activating antigen-4, VLA-4), and/or MUC-1 on MM cell lines; as well as CD106 (VCAM-1) and CD54 (ICAM-1) expression on BMSCs. This resulted in increased (2-4-fold) per cent specific binding of MM cells to BMSCs, with related IL-6 secretion. Importantly, the proteasome inhibitor PS-341 abrogated TNFalpha-induced NF-kappaB activation, induction of ICAM-1 or VCAM-1, and increased adhesion of MM cells to BMSCs. Agents which act to inhibit TNFalpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.
Similar articles
- Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC. Tai YT, et al. Cancer Res. 2006 Jul 1;66(13):6675-82. doi: 10.1158/0008-5472.CAN-06-0190. Cancer Res. 2006. PMID: 16818641 - Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS. Nguyen AN, et al. Exp Cell Res. 2006 Jun 10;312(10):1909-23. doi: 10.1016/j.yexcr.2006.02.026. Epub 2006 Apr 4. Exp Cell Res. 2006. PMID: 16600214 - Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation.
Lee CW, Lin WN, Lin CC, Luo SF, Wang JS, Pouyssegur J, Yang CM. Lee CW, et al. J Cell Physiol. 2006 Apr;207(1):174-86. doi: 10.1002/jcp.20549. J Cell Physiol. 2006. PMID: 16288471 - Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Hideshima T, et al. Semin Oncol. 2001 Dec;28(6):607-12. doi: 10.1016/s0093-7754(01)90033-8. Semin Oncol. 2001. PMID: 11740818 Review. - The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR, Ma HM, Vescio R. Berenson JR, et al. Semin Oncol. 2001 Dec;28(6):626-33. doi: 10.1016/s0093-7754(01)90036-3. Semin Oncol. 2001. PMID: 11740821 Review.
Cited by
- Tracing from Periphery to Cortex: Application of Herpes Simplex Virus to Somatosensory Neural Networks.
Chen Y, Chen Q, Song Y, Wang H, Hu X, Wang K, Wu X, Xu F, Bao L, Zhang X. Chen Y, et al. Neurosci Bull. 2024 Oct 16. doi: 10.1007/s12264-024-01309-9. Online ahead of print. Neurosci Bull. 2024. PMID: 39414760 No abstract available. - It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.
Choa R, Panaroni C, Bhatia R, Raje N. Choa R, et al. Blood Adv. 2023 Sep 26;7(18):5510-5523. doi: 10.1182/bloodadvances.2023010822. Blood Adv. 2023. PMID: 37493975 Free PMC article. Review. - [Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment].
He NH, Zhou W. He NH, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 May;54(3):475-481. doi: 10.12182/20230560207. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37248571 Free PMC article. Review. Chinese. - A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J, Zhou J, Zhang M, Zhang Y, Zeng Y, Li S, Xu K, Yao R. Gao J, et al. Mol Cell Biochem. 2024 Apr;479(4):843-857. doi: 10.1007/s11010-023-04764-6. Epub 2023 May 19. Mol Cell Biochem. 2024. PMID: 37204666 - Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma.
Kropivsek K, Kachel P, Goetze S, Wegmann R, Festl Y, Severin Y, Hale BD, Mena J, van Drogen A, Dietliker N, Tchinda J, Wollscheid B, Manz MG, Snijder B. Kropivsek K, et al. Nat Cancer. 2023 May;4(5):734-753. doi: 10.1038/s43018-023-00544-9. Epub 2023 Apr 20. Nat Cancer. 2023. PMID: 37081258 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous